Geron Corp - GERN STOCK NEWS

Geron , a biopharmaceutical company, announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted non-statutory stock options for 222,660 shares to new employees as of June 19, 2024. The exercise price is $4.49 per share, equal to the closing price of Geron stock on the grant date. These options have a 10-year term and vest over four years, with 12.5% vesting after six months and the remainder vesting in equal installments over 42 months, subject to continued employment. The grants are part of Geron's 2018 Inducement Award Plan.

Geron has announced FDA approval for RYTELO™ (imetelstat), the first telomerase inhibitor, to treat adults with lower-risk myelodysplastic syndromes (MDS) suffering from transfusion-dependent anemia. The approval covers ESA ineligible and relapsed/refractory patients, regardless of ring sideroblast status. The IMerge Phase 3 clinical trial revealed significant improvements in transfusion independence and hemoglobin levels. The common Grade 3/4 adverse reactions were thrombocytopenia and neutropenia but were generally manageable. A conference call is scheduled for June 7, 2024, at 8 am ET to discuss these developments.

Geron (Nasdaq: GERN) announced the grant of non-statutory stock options to purchase 2,910,780 shares of common stock as inducements for newly hired employees. The options were granted on May 15, 2024, at an exercise price of $3.90 per share, matching the closing price on the grant date. The options, which have a 10-year term, will vest over four years, starting with 12.5% on the six-month anniversary of employment, followed by equal monthly installments over the next 42 months. These inducements are in line with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.

Geron (Nasdaq: GERN) reported financial results for the first quarter of 2024, including a net loss of $55.4 million and revenues of $304,000. The company has completed commercial team onboarding and is preparing for the potential U.S. launch of imetelstat pending FDA approval. The Phase 3 IMpactMF trial continues with updated timelines. Geron expects total operating expenses for fiscal year 2024 to be $270-280 million.

Geron (Nasdaq: GERN) will announce its first quarter 2024 financial results and business highlights on May 2, 2024. The company will host a conference call to discuss the results and highlights at 8:00 a.m. ET the same day.

Geron (GERN) reported granting non-statutory stock options to purchase 243,000 shares of Geron common stock as inducements to newly hired employees. The options were granted at an exercise price of $3.68 per share and have a 10-year term, vesting over four years. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.

Geron (GERN) announces CEO's participation in upcoming virtual investor conferences. John A. Scarlett, M.D., to present at Needham Virtual Healthcare Conference and Stifel's Targeted Oncology Days. Webcasts will be available on the company's website.

Geron (GERN) announces the pricing of an underwritten offering of common stock and pre-funded warrants. The offering includes 41,999,998 shares at $3.00 per share and pre-funded warrants for 8,002,668 shares at $2.999 per warrant. The offering involves various investment firms and is set to close soon.

Geron Corporation's imetelstat receives positive vote from FDA Oncologic Drugs Advisory Committee for the treatment of transfusion-dependent anemia in adult patients with LR-MDS. The IMerge Phase 3 trial results show significant clinical benefit with improved red blood cell transfusion independence and hemoglobin levels. The PDUFA target action date is set for June 16, 2024, indicating a potential new treatment option for patients with unmet medical needs.